Carin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carin

Quick Facts

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Orally Disintegrating Tablet (ODT)
Pharmacological class Selective peripheral H1-receptor Antagonist
Common use Relief and management of typical allergy symptoms
Origin Synthetic, Second-Generation Antihistamine

What is Carin and What Type of Drug is it?

Carin is a commercial brand name for a medicinal preparation whose sole active compound is Loratadine, a chemically distinct ingredient with anti-allergic properties. This medication is precisely classified within the drug class of second-generation antihistamines and functions specifically as a highly selective peripheral H1-receptor antagonist.

A key differentiating feature of the Loratadine component is its non-sedating profile. The drug is designed with limited ability to cross the blood-brain barrier, allowing it to target allergic reactions in peripheral tissues. This makes Carin particularly suited for symptom relief without impairment of daytime alertness, a significant difference from older first-generation antihistamines.

Composition, Forms, and General Purpose

The Carin preparation is formulated as a single product, containing only Loratadine as the primary therapeutic agent. It is widely available for oral administration in multiple dosage forms, including the standard tablet, the convenient syrup, and the Orally Disintegrating Tablet (ODT). The ODT and syrup forms are often utilized to accommodate specific patient needs, such as the pediatric population or individuals who have difficulty swallowing pills.

Its general purpose is the management and relief of typical allergy symptoms. It achieves this by the mechanism of preventing the body's self-released Histamine from binding to its peripheral receptors. This action is beneficial in scenarios requiring continuous management of recurrent allergic discomfort, thereby supporting the quality of life during periods of high allergen exposure.

What side effects are possible with Carin?

Possible Side Effects and Safety Information

The official safety profile of Carin, which contains the active ingredient Loratadine, is established by government regulatory bodies (such as the EMA and FDA) and classifies documented adverse reactions by frequency and physiological system.

Category Regulatory Description
Common Adverse Reactions These are the most frequently reported effects, including Headache, Somnolence (drowsiness), and Fatigue in adults and adolescents. In the pediatric population (ages 2–12), Nervousness and Headache are also commonly observed.
System-Organ Classes Adverse reactions are grouped by the systems affected, such as Nervous System Disorders (Headache, Somnolence), Gastrointestinal Disorders (Dry mouth), and General Disorders (Fatigue).
Serious Adverse Reactions Very Rare (may affect up to 1 in 10,000 people) reactions are documented, including severe Hypersensitivity reactions (e.g., Angioedema, Anaphylaxis), Abnormal hepatic function, and Seizures (convulsions).
Safety Restrictions The medicine is contraindicated in individuals with a known hypersensitivity to Loratadine. Caution is necessary when the drug is administered to patients with severe hepatic impairment or renal impairment.
Safety Considerations Because the drug is excreted in breast milk, its use is generally not recommended in breastfeeding women. Furthermore, due to the potential for antihistamines to interfere with test results, the official safety documentation recommends discontinuation for at least 48 hours before skin allergy testing.

Regulatory Safety Summary:

  • The most frequently reported adverse reactions are classified as Common, primarily affecting the Nervous System and leading to Fatigue.
  • The regulatory profile includes Very Rare but serious events such as Anaphylaxis and issues related to Abnormal hepatic function.
  • Official labeling specifically mandates safety consideration for patients with severe hepatic or renal impairment.

The regulatory documentation structures the safety profile by providing explicit classifications of adverse reactions based on their frequency and the body system affected. This provides a structured view of the medicine's documented risk characteristics and defines the high-level constraints and patient groups requiring safety observation.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation describes the specific signs and actions required in cases of Carin (Loratadine) overdosage. The officially documented clinical manifestations reported include somnolence (drowsiness), headache, and tachycardia (rapid heart rate). An excessive dose is also noted to potentially increase the occurrence of anticholinergic symptoms.

In the event of an overdose, regulatory authorities mandate that individuals seek medical help or contact a Poison Control Center right away.

Documented Overdose Manifestations Emergency Action Mandate
Somnolence, Headache, Tachycardia Seek medical help immediately
Increased Anticholinergic Symptoms Contact a Poison Control Center

Management in an overdose scenario focuses on general symptomatic and supportive measures. The official labeling indicates that there is no specific antidote for Loratadine. Procedures such as the administration of activated charcoal as a slurry with water and gastric lavage may be considered to remove unabsorbed medicine. Furthermore, continued medical monitoring of the patient is recommended after initial emergency treatment. Loratadine is officially noted as not eliminated by haemodialysis. For children specifically, the regulatory text specifies that physiologic saline solution is the lavage solution of choice if gastric lavage is performed.

Therapeutic Uses of Carin

What Carin Treats: Main Uses and Benefits

The therapeutic role of Carin (Loratadine) is to provide temporary symptomatic relief from symptoms caused by allergies. The medication addresses key conditions including allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria (hives).


Managing Symptom Clusters

Carin is applied across domains where additional symptomatic support is needed, primarily to ease symptoms related to inflammatory or irritative states. It helps address symptom clusters that may become intense or disruptive, such as a runny nose, frequent sneezing, itchy eyes, and skin itching (pruritus). This is relevant in contexts involving heightened systemic burden, such as during peak hay fever season or continuous indoor allergen exposure.


Functional Benefit and Patient Comfort

Applicable within clinical settings that involve acute or disruptive symptom patterns, Carin offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is commonly used to help with recurrent manifestations, providing supportive relief without the level of drowsiness generally associated with some alternative treatments. This generally assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Symptom Focus Context of Use
Nasal/Ocular Discomfort Seasonal and Year-Round Environmental Triggers
Dermal Pruritus Managing Episodic or Chronic Allergic Skin Reactions

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Carin (Loratadine)

The official regulatory eligibility for Carin (Loratadine) is determined by the patient's age, organ function, and specific medical conditions, as defined in governmental prescribing information.

Populations for whom use is contraindicated:

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to Loratadine, its active metabolite (Desloratadine), or any excipients in the formulation.

Age-Related Eligibility:

  • Adults and Adolescents (ge 12 years): Fully eligible for use.
  • Children (2 to 12 years): Eligible for use, typically with age- and weight-dependent dosing. Use in children younger than 2 years of age is generally not recommended as safety and efficacy have not been established.

Conditional Use and Restrictions:

  • Organ Function Status: Patients with severe hepatic impairment or significant renal impairment are considered a restricted-use population and require careful consideration by a healthcare professional due to the potential for reduced clearance.
  • Pregnancy: Use is generally avoided as a precautionary measure, though some agencies note data suggesting no major teratogenic risk. Use during pregnancy should occur only if clearly needed.
  • Lactation (Breastfeeding): Use is not recommended because Loratadine and its active metabolite are excreted into breast milk.
  • Phenylketonuria (PKU): Patients with PKU should be aware that some formulations, such as Orally Disintegrating Tablets (ODT), contain phenylalanine and must be used with caution.
  • Allergy Testing: Use must be discontinued at least 48 hours prior to allergy skin testing, as the drug can interfere with the diagnostic results.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Carin (Loratadine) highlights documented pharmacokinetic interactions and specific administration constraints. The drug is metabolized primarily by the CYP3A4 and CYP2D6 enzyme systems. Co-administration with known inhibitors of these enzymes, such as Ketoconazole, Erythromycin, and Cimetidine, is officially reported to cause a substantial increase in loratadine plasma concentrations. However, this exposure increase was documented in controlled trials as being without clinically significant changes in electrocardiographic parameters.


The interaction structure includes administration timing constraints and documented food effects. Loratadine administration must be discontinued for at least 48 hours before any diagnostic skin testing procedure to prevent pharmacodynamic interference with the dermal reactivity index. Separately, consumption of a high-fat meal is documented to increase the drug's systemic bioavailability (AUC). The regulatory data also notes that loratadine has no potentiating effects on psychomotor performance when co-administered with alcohol.


Population-specific interaction notes relate to altered drug clearance. Individuals with severe hepatic impairment exhibit reduced clearance, leading to doubled systemic exposure. Similarly, patients with chronic renal impairment show increased systemic exposure, a pharmacokinetic change that may influence the relevance of potential drug-drug interactions.

Mechanism of Action

Carin functions as a modulator of the Constitutive Androstane Receptor (CAR), a nuclear receptor and xenosensor primarily expressed in hepatocytes. The interaction type is typically an agonist or inverse agonist, inducing ligand-dependent or ligand-independent activation.

Activation involves the dissociation of the cytosolic CAR-HSP90-CCRP complex. Dephosphorylation, often mediated by protein phosphatase 2A (PP2A), facilitates the nuclear translocation of CAR.

Intracellularly, CAR forms a heterodimer with the Retinoid X Receptor (RXR). This dimer binds to specific DNA sequences, such as the xenobiotic responsive element (XRE), initiating the transcriptional upregulation of target genes.

This downstream cascade includes increased gene expression of drug-metabolizing enzymes, notably Cytochrome P450 (CYP) enzymes like CYP2B6 and phase II enzymes such as UGT1A1. This gene induction results in system-level physiological consequences characterized by the modulation of xenobiotic and endobiotic clearance, as well as shifts in glucose and lipid homeostasis via the regulation of related metabolic pathways.

Dosage and Administration Information

How Carin is Used

Carin is a medication administered by the oral route, available in several formulations, including the standard 10 mg tablet, a 5 mg/5 mL syrup (oral solution), and the 10 mg Orally Disintegrating Tablet (ODT). Correct use follows the dosing schedule and specific administration requirements.

Dosing and Frequency

The standard regimen for Carin is once daily (QD), and the maximum recommended dose for adults and older children is not to be exceeded in a 24-hour period. Doses are typically taken without regard to mealtime.

Patient Group Standard Daily Dose Note on Administration
Adults and Adolescents (ge 12 years) 10 mg once daily May be taken with or without food.
Children 6 to 11 years 10 mg once daily Syrup or chewable forms may be used.
Children 2 to 5 years (le 30 kg) 5 mg once daily Liquid formulations are often recommended.

Administration Requirements and Adjustments

Proper use depends on the formulation. The syrup is measured using a calibrated dosing device. The Orally Disintegrating Tablet (ODT) is placed on the tongue to disintegrate before swallowing.

Dose modification applies in specific patient populations due to altered drug clearance:

  • Severe Hepatic or Renal Impairment (ge 6 years): The starting dose is reduced to 10 mg every other day (Q48h).
  • Procedural Condition: Administration is discontinued for a minimum of 48 hours before any planned allergy skin test to prevent interference with the diagnostic results.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Carin

Carin in Conditions with Episodic Symptoms

The research examined outcomes in the context of conditions characterized by fluctuating or episodic manifestations. These investigations were primarily relevant in trials assessing short-term or episodic symptom patterns, often focused on studies conducted during periods of increased symptom activity where symptoms become more noticeable. The research examined outcomes capturing phases of heightened symptom activity, using measures applied in studies examining patient-reported experiences of outcomes related to physical discomfort.

These studies monitored outcomes in populations with conditions presenting with cycles of stability and flare-ups. The findings describe patterns observed in the studies regarding outcomes describing episodic or acute changes during the defined time intervals. Research describes changes measured during the study period, and the studies tracked how symptoms evolved in the observed populations.

The limitations of the current research include: Follow-up durations were limited in key investigations, meaning long-term effects are not fully established. Limited information is available regarding how findings may apply to specific patient subgroups, and certainty remains low regarding long-term consistency. The results apply only to the populations studied, and the evidence quality varies across studies, highlighting that further research is ongoing and needed.

Carin and Outcomes Related to Daily Functioning

A separate area of research focused on outcomes in contexts used in observational settings evaluating daily-life functioning for individuals with conditions marked by functional limitations. This research focused on outcomes reflecting daily functioning or activity level, as well as patient-reported outcomes describing perceived discomfort. These investigations were evaluated in individuals living with conditions where symptoms may vary in intensity.

The research describes how the patients in these observed groups reported their outcomes related to systemic or functional imbalance. The data show patterns related to how daily functioning was observed in the studied populations, and findings help contextualize how patients reported their experience during the study period. Some studies describe patterns related to outcomes reflecting daily functioning or activity level as they were studied for short-term evolution.

This research describes observations but has limitations. Many of these investigations had sample sizes were modest, and data for certain groups remain insufficient. The subgroup findings are uncertain, and comparative evidence is lacking to fully understand this profile alongside other potential options. This means that while the research describes group patterns observed so far, individual outcomes are not determined by these findings. Evidence is still emerging in this area.

Key Studies & References Loratadine - StatPearls - NCBI Bookshelf (Review of Indications and Evidence)

Frequently Asked Questions (FAQ)

Common questions about Carin (FAQ)

Q: Is Carin used for conditions other than the primary one listed in the official documents?

Regulatory documents state that this medicine is officially indicated for the relief and management of symptoms related to allergic rhinitis, which is commonly known as hay fever. It is also indicated for treating symptoms associated with chronic idiopathic urticaria (hives). Official sources define the scope of use based on these specific conditions.

Q: Is Carin considered a common or specialized type of drug?

The drug is widely available over-the-counter (OTC) and is classified as a second-generation antihistamine. It is used for the common purpose of managing typical allergy symptoms. This broad availability and common usage context indicate its general, non-specialized role in allergy relief.

Q: Can Carin be taken for a long period of time?

Official documents note that during long-term treatment, no clinically significant changes were observed in vital signs or laboratory tests. However, the existing research is described as having limitations in long-term follow-up duration. This means that long-term consistency and effects are not fully established by the current evidence base.

Q: What is the experience like when first starting Carin?

The body may begin to feel the effects within one to three hours of administration, with common initial side effects including headache, somnolence (drowsiness), and fatigue. These are the most frequently reported effects described in the official safety profile.

Q: How long does it usually take to feel the effects of Carin?

Official pharmacokinetic data indicates that the onset of action is typically within one to three hours of administration. This means the medicine begins to exert its effects in the body relatively quickly after being taken.

Q: If I miss a dose of Carin, what generally happens?

Official directions for a missed dose are not always explicitly detailed in regulatory summaries. However, a key requirement stated in the administration guidelines is that the maximum recommended dose should not be exceeded in a 24-hour period.

Q: Are there specific foods or drinks that should be avoided while taking Carin?

Official regulatory information states that a high-fat meal can increase the drug's systemic availability, which is a consideration for administration. Separately, Loratadine is documented as having no potentiated effects on psychomotor performance when co-administered with alcohol.

Q: Can Carin be taken with over-the-counter pain relievers?

The drug is metabolized by CYP enzymes, and co-administration with other medicines, including over-the-counter pain relievers, is suggested to be reviewed by a healthcare professional to assess potential pharmacokinetic interactions.

Q: Is Carin safe for people with high blood pressure?

The active ingredient in this medicine, when used alone, is not documented in regulatory sources to cause an increase in blood pressure. Safety considerations apply mainly to patients with severe hepatic or renal impairment, who require careful professional consideration.

Q: Is it okay to take Carin if I also take supplements?

Official guidance suggests that supplements, including herbal remedies, be reviewed by a healthcare professional. This is due to limited specific data on combinations, as these products are not tested in the same way as approved medicines for potential interaction effects.

Q: Do studies suggest Carin loses effectiveness over time?

The studies that supported the drug's use examined outcomes over short-term periods. The current research is described as having limitations in long-term follow-up duration, meaning long-term consistency of effects is not fully established by the evidence.

Q: What kind of research has been done on Carin in different age groups?

Research has focused on outcomes in adult, adolescent, and pediatric populations (ages 2–12). Official regulatory documents also note that the pharmacokinetic profile in healthy older adult volunteers is described as comparable to that of healthy younger volunteers.

Q: Is Carin available as a generic medicine?

Yes, the active ingredient in Carin, which is Loratadine, is widely available. It is found in multiple generic formulations that have been approved by the regulatory authority.

Q: How long does Carin stay in your system after stopping?

Official pharmacokinetic data indicates that the active ingredient, Loratadine, has a mean elimination half-life of approximately 8.4 hours in healthy adults. Its active metabolite, which also contributes to the effect, has a longer mean elimination half-life of approximately 28 hours.

Q: Does Carin have a boxed warning in official FDA documents?

Official FDA labeling for this medicine does not include a Boxed Warning. This type of warning, sometimes called a Black Box Warning, is a safety measure the FDA uses to highlight serious risks for certain drugs.

Q: Does Carin interact with common prescription medications like antidepressants?

The drug is metabolized by specific liver enzymes that are necessary for the breakdown of many other medications, including certain antidepressants. Due to potential interactions, consulting a healthcare professional is suggested to assess the combination with other prescriptions.

Q: What does the research say about Carin's use in younger adults?

Research has focused on outcomes related to episodic symptoms and daily functioning in populations including younger adults. However, the evidence is still described as emerging, with limited data available for specific patient subgroups.

Q: Are there any known interactions with herbal products or natural remedies?

Official guidance notes that there is limited specific information on interactions with herbal remedies or supplements. A review with a healthcare professional is suggested regarding these combinations, as dedicated interaction testing is often lacking.

Q: Do I need to change my daily routine much while taking Carin?

The main procedural change required is to discontinue use for at least 48 hours before any planned allergy skin test. Doses are typically taken without regard to mealtime. Furthermore, the drug has no potentiating effects documented with alcohol.

Q: Is Carin addictive or habit-forming according to official sources?

Official regulatory bodies have not classified this drug as a controlled substance. Correspondingly, the regulatory documentation does not describe it as addictive or habit-forming.

Q: What does the term 'contraindication' mean for Carin?

A contraindication is an official restriction that describes a condition or factor that renders the drug use inadvisable or potentially harmful. For Carin, this includes a known hypersensitivity to the medicine or any of its ingredients.

Q: Can Carin affect my ability to drive or operate machinery?

Somnolence (drowsiness) and fatigue are classified as common adverse reactions documented in the safety profile. Official guidance advises that patients should avoid driving or operating machinery until the effects of somnolence and fatigue have fully subsided.

Q: Are there any common reasons why Carin might not work for someone?

Official documentation notes that the drug is strictly contraindicated for those with a known hypersensitivity. The research evidence also indicates that individual outcomes are not determined by group findings and results apply only to the populations studied, suggesting individual variability in response is possible.

Q: What is the expected timeline for Carin's full effect to be noticeable?

Pharmacodynamic data indicates that the peak effect of the medicine is typically reached within 8 to 12 hours after administration. This timeline represents when the concentration of the drug's active components in the body is at its highest.

Q: Does Carin cause weight gain or weight loss?

The regulatory safety profile lists increased appetite as an uncommon adverse reaction, meaning it may affect up to 1 in 100 people. However, weight gain or weight loss itself is not listed as a common or frequent side effect in the official documentation.

Q: Can Carin cause mood changes or affect mental health?

The safety profile lists nervousness as a common psychiatric adverse reaction and insomnia (sleeplessness) as an uncommon reaction. These effects are grouped under the relevant system-organ classes in official regulatory documents.

Q: What is the significance of the research evidence that supports Carin's use?

The research examined outcomes in conditions with episodic symptoms and also studied outcomes related to daily functioning. This body of evidence describes patterns observed in the studies regarding symptom evolution and patient-reported experiences, supporting its approved uses.

Q: Why is the drug intended only for a specific population?

The patient population is restricted by official eligibility rules regarding age (not recommended for children younger than 2 years) and organ function (severe hepatic or renal impairment requires caution). It is also restricted for individuals with existing conditions like known hypersensitivity.

Q: Do official patient information leaflets discuss long-term side effects?

The regulatory documentation lists adverse reactions primarily by frequency classification, such as Common or Very Rare, rather than by duration. Studies have been noted to have limited follow-up durations, meaning long-term effects are not fully established by the evidence.

Q: Are there restrictions on taking Carin with cold or flu medicines?

The drug is metabolized by specific liver enzymes, and certain ingredients in cold or flu medicines could be enzyme inhibitors. These inhibitors may potentially increase the concentration of this medicine in the body.

Q: How quickly does Carin start to break down in the body?

Following oral administration, the drug undergoes extensive first-pass metabolism, which means it is quickly broken down in the body, mainly by the CYP3A4 and CYP2D6 enzymes. The mean elimination half-life for the active ingredient is approximately 8.4 hours.

Q: What is the general duration of effect for a single dose of Carin?

Pharmacodynamic data for a single dose indicates that the duration of effect is up to 24 hours. This aligns with the typical once-daily dosing regimen that is outlined in the official prescribing information.

Q: Does Carin show up on drug screening tests?

The medicine is not classified as a controlled substance by official regulatory bodies. Standard drug screening tests typically target controlled substances or specific classes of drugs not related to this medicine.

Q: What is the purpose of the 'Risk Evaluation and Mitigation Strategy' (REMS) if Carin has one?

The drug does not currently have a mandated Risk Evaluation and Mitigation Strategy (REMS). A REMS is a drug safety program the FDA may require for certain medications to ensure that their benefits outweigh their risks in the patient population.

Q: Is Carin appropriate for older adult patients?

Most adults, including older adult patients, are eligible for use. Regulatory documentation notes that the pharmacokinetic profile in healthy older adult volunteers is comparable to that of healthy younger volunteers, suggesting similar drug processing in the body.

Q: Are there specific laboratory tests that need to be done while on Carin?

Official instructions require the medicine to be discontinued at least 48 hours before allergy skin testing. Furthermore, because dose adjustments may be necessary for patients with liver or kidney disease, monitoring of these conditions may be required.

How should Carin be stored and disposed of?

Storage and Disposal of Carin

Official regulatory documents define specific conditions for storing Carin (Loratadine) to ensure product stability.


Storage Requirements

Item Official Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection The product must be kept out of the reach and sight of children. Store in the original container to protect it from excessive moisture and light.
Handling Syrups must be kept tightly closed. Do not store the medicine in high-humidity areas, such as a bathroom.

Disposal Instructions

Disposal of unused or expired Carin should follow official governmental guidance. The preferred method is to utilize a drug take-back program. If a program is unavailable, medicine should be mixed with an undesirable substance (like coffee grounds), sealed in a bag, and discarded with household trash. Do not flush the medication down a toilet or sink unless specifically instructed by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carin found in:

A-Z Index: